Watch: McMaster researchers say thank you to Charles and Margaret Juravinski

Unapproved peptides that lack safety and efficacy data carry substantial risks and belong in a laboratory, not your body, Phillips warns.

The funding will accelerate the move toward human trials, enabling preclinical studies, regulatory preparation and early-phase clinical trial design.

Patients who had the procedure experienced a significantly better quality of life and less severe post-thrombotic syndrome, a painful condition that affects 20 to 50 per cent of people who had a deep vein thrombosis.